Roth Capital Raises Price Target on Lannett (LCI) Following Acquisition of Kremers Urban Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion
September 2, 2015 4:30 PM EDTPHILADELPHIA, Pa., Sept. 2, 2015 /PRNewswire/ --
Transaction Highlights:
Substantially increases, diversifies revenue base with highly profitable specialty products Expands pipeline with exciting products Near-term growth potential with 11 product applications pending at the FDA, of which five include Paragraph IV certifications Provides medium and longer term growth potential with 17 product candidates in development, including eight controlled substances Adds development expertise in difficult to formulate generics, including various dosage forms Accretive to adjusted EPS in fiscal 2016 in the... More